On January 4, 2022, the US FDA granted breakthrough therapy designation to Teliso‐V for patients with advanced/metastatic EGFR wild‐type nonsquamous NSCLC who have disease progression during or after platinum‐based therapy and c‐Met overexpression, based on supporting data from the ongoing phase II LUMINOSITY clinical trial (NCT03539536) presented at AACR in 2021. This evidence concerns the gene MET and non-small cell lung carcinoma.